Novartis Investigative Site

Kofu, Yamanashi 400-8506

1 studies enrolling now · 2 studies all time

What they study most

Non-segmental Vitiligo, Primary Immune Thrombocytopenia

Studies at this site

• A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo — Recruiting now
• A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids — Running, not enrolling